

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奥赛图(北京)医药科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

NOTICE OF THE 2023 SECOND EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that the 2023 second extraordinary general meeting (the “EGM”) of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the “**Company**”) will be held with the combination of a physical meeting at the conference room of 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, PRC and a virtual meeting online at 10:00 a.m. on Tuesday, December 12, 2023 for the following purposes of considering and, if deemed appropriate, approving the following resolutions.

SPECIAL RESOLUTIONS

1. To consider and approve the amendments to the existing articles of association of the Company.
2. To consider and approve the further amendments to the articles of association which will take effect upon completion of the proposed Issue of A Shares.
3. To consider and approve the amendments to each of the existing rules of procedures:
 - 3.1. To consider and approve the proposed amendments to “Rules of Procedures for Shareholders’ General Meeting”;
 - 3.2. To consider and approve the proposed amendments to “Rules of Procedures for the Board of Directors Meeting”; and
 - 3.3. To consider and approve the proposed amendments to “Rules of Procedures for the Supervisory Committee Meeting”.
4. To consider and approve the further amendments to each of the rules of procedures which will take effect upon completion of the proposed Issue of A Shares:
 - 4.1. To consider and approve the proposed further amendments to “Rules of Procedures for Shareholders’ General Meeting”;

- 4.2. To consider and approve the proposed further amendments to “Rules of Procedures for the Board of Directors Meeting”; and
- 4.3. To consider and approve the proposed further amendments to “Rules of Procedures for the Supervisory Committee Meeting”.

ORDINARY RESOLUTIONS

5. To consider and approve the proposed guarantee for subsidiaries of the Company:
 - 5.1 To consider and approve the proposed guarantee in relation to the application for a RMB60 million consolidated credit facility by Biocytogen Jiangsu Co., Ltd. (百奧賽圖江蘇基因生物技術有限公司) from Bank of Nanjing; and
 - 5.2 To consider and approve the proposed guarantees involved in credit applications to banks by other subsidiaries.
6. To consider and approve the proposed election of the following directors as directors for the second session of the board of directors of the Company:
 - 6.1. To consider and approve the proposed election of Dr. Shen Yuelei as an executive director of the Company;
 - 6.2. To consider and approve the proposed election of Dr. Ni Jian as an executive director of the Company;
 - 6.3. To consider and approve the proposed election of Dr. Zhang Haichao as an executive director of the Company;
 - 6.4. To consider and approve the proposed election of Mr. Wei Yiliang as a non-executive director of the Company;
 - 6.5. To consider and approve the proposed election of Dr. Zhou Kexiang as a non-executive director of the Company;
 - 6.6. To consider and approve the proposed election of Ms. Zhang Leidi as a non-executive director of the Company;
 - 6.7. To consider and approve the proposed election of Mr. Hua Fengmao as an independent non-executive director of the Company;
 - 6.8. To consider and approve the proposed election of Dr. Yu Changyuan as an independent non-executive director of the Company; and

- 6.9. To consider and approve the proposed election of Ms. Liang Xiaoyan as an independent non-executive director of the Company.
7. To consider and approve the proposed election of the following non-employee representatives supervisors as non-employee representatives supervisors for the second session of the supervisory committee of the Company:
- 7.1. To consider and approve the proposed election of Ms. Li Yan as a non-employee representatives supervisor of the Company; and
- 7.2. To consider and approve the proposed election of Dr. Yao Jiawei as a non-employee representatives supervisor of the Company.

Yours faithfully,
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuele
*Chairman of the Board, Chief Executive Officer and
Executive Director*

Hong Kong, November 23, 2023

Notes:

1. Unless the context otherwise stated, capitalized terms used in this notice shall have the meanings as those defined in the circular (the “**Circular**”) of the Company dated November 23, 2023.

Registered Shareholders are requested to provide a valid email address of himself/herself/itself or his/her/its proxy (except for the appointment of the chairman of the EGM) for the proxy to receive the login access code to participate online in the e-Meeting System.

Registered Shareholders will be able to attend the EGM, vote and submit questions online via the designated URL (<https://spot-emeeting.tricor.hk>) by using the username and password provided on the notification letter sent by the Company.

Non-registered holders whose H Shares are held in the Central Clearing and Settlement System through banks, brokers, custodians or Hong Kong Securities Clearing Company Limited may also be able to attend the EGM, vote and submit questions online. In this regard, they should consult directly with their banks, brokers custodians, nominees or HKSCC Nominees Limited through which their shares are held (as the case may be) (collectively the “**Intermediary**”) and instruct the Intermediary to appoint them as proxy or corporate representative to attend and vote at the EGM electronically and in doing so, they will be asked to provide their email address, before the time limit required by the relevant Intermediary. Details regarding the e-Meeting System including the login details will be emailed to them by the Company’s H Share Registrar, Tricor Investor Services Limited.

2. For the purpose of determining the entitlement to attend and vote at the EGM, the register of members of the Company will be closed from Thursday, December 7, 2023 to Tuesday, December 12, 2023 (both days inclusive), during which period no transfer of shares will be registered. In order to be eligible to attend and vote at the EGM, all transfers of shares, accompanied by the relevant share certificates, must be lodged with the Company’s H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (for H Shareholders), or to the Company’s registered office at 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, PRC (for the Domestic and Unlisted Shareholders), for registration not later than 4:30 p.m. on Wednesday, December 6, 2023.
3. Shareholders who are entitled to attend and vote at the EGM may appoint one or more proxies to attend and vote on their behalves. A proxy need not be a shareholder of the Company. If more than one proxy is appointed, the number of shares in respect of which each such proxy so appointed must be specified in the relevant form of proxy. Every shareholder present in person or by proxy shall be entitled to one vote for each share held by him.
4. The instrument appointing a proxy must be in writing under the hand of a Shareholder or his attorney duly authorised in writing. If the Shareholder is a legal person, that instrument must be executed either under its seal or under the hand of its director or other attorney duly authorised to sign the same on its behalf.
5. In order to be valid, the form of proxy, together with a power of attorney or other authority, if any, under which it is signed, or a certified copy of such power or authority must be deposited at the Company’s H share registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (for H Shareholders), or to the Company’s registered office at 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, PRC (for the Domestic and Unlisted Shareholders), or via the designated URL (<https://spot-emeeting.tricor.hk>) by using the username and password provided on the notification letters sent by the Company (for all Shareholders) as soon as possible and in any event no later than 10:00 a.m. on Monday, December 11, 2023 (Hong Kong time) or no less than 24 hours before the time appointed for holding the above mentioned meeting or any adjournment thereof. Completion and return of a form of proxy will not preclude a Shareholder from attending and voting at the EGM or any adjournment thereof, should they so wish.
6. All resolutions at the EGM will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Listing Rules. The results of the poll will be published on the websites of the Stock Exchange and the Company in accordance with the Listing Rules.
7. References to time and dates in this notice are to Hong Kong time and dates.

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.